Pharmaceuticals company Dr. Reddy's Laboratories announced Q1FY25 results: Revenues: Rs 76,727 million [Up: 14% YoY; 8% QoQ] Gross Margin: 60.4% [Q1FY24: 58.7%; Q4FY24: 58.6%] SG&A; Expenses: Rs 22,691 million [Up: 28% YoY; 11% QoQ] R&D; Expenses: Rs 6,193 million [8.1% of Revenues] EBITDA: Rs 21,599 million [28.2% of Revenues] Profit before Tax: Rs 18,821 million [Up: 2% YoY; 18% QoQ] Profit after Tax: Rs 13,920 million- [Down: 1% YoY; Up: 7% QoQ) Commenting on the results, Co-Chairman & MD, G V Prasad said: "We had a good start to the new fiscal year and our growth & profitability was mainly driven by our generics business. We continue to strengthen our core businesses and have made strategic investments in biologics, consumer healthcare and innovation to drive patient impact and value creation." Result PDF
Conference Call with Dr. Reddy's Laboratories Ltd. Management and Analysts on Q1FY25 Performance and Outlook. Listen to the full earnings transcript.